NO20043889L - Farmasoytiske blandinger omfattende 2-(4-etoksy-fenyl)-3-(4-metansulfonyl-fenyl)-pyrazolo' 1,5-bipyridazin i nanopartikkelform - Google Patents

Farmasoytiske blandinger omfattende 2-(4-etoksy-fenyl)-3-(4-metansulfonyl-fenyl)-pyrazolo' 1,5-bipyridazin i nanopartikkelform

Info

Publication number
NO20043889L
NO20043889L NO20043889A NO20043889A NO20043889L NO 20043889 L NO20043889 L NO 20043889L NO 20043889 A NO20043889 A NO 20043889A NO 20043889 A NO20043889 A NO 20043889A NO 20043889 L NO20043889 L NO 20043889L
Authority
NO
Norway
Prior art keywords
phenyl
bipyridazine
pyrazolo
methanesulfonyl
ethoxy
Prior art date
Application number
NO20043889A
Other languages
English (en)
Norwegian (no)
Inventor
Simon Joseph Holland
Jonathan Appleby
Martin Rolfe Hill
Stephanie Lynn Pearson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20043889L publication Critical patent/NO20043889L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20043889A 2002-03-15 2004-09-16 Farmasoytiske blandinger omfattende 2-(4-etoksy-fenyl)-3-(4-metansulfonyl-fenyl)-pyrazolo' 1,5-bipyridazin i nanopartikkelform NO20043889L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206200.8A GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions
PCT/EP2003/002698 WO2003077920A1 (en) 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form

Publications (1)

Publication Number Publication Date
NO20043889L true NO20043889L (no) 2004-09-16

Family

ID=9933079

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043889A NO20043889L (no) 2002-03-15 2004-09-16 Farmasoytiske blandinger omfattende 2-(4-etoksy-fenyl)-3-(4-metansulfonyl-fenyl)-pyrazolo' 1,5-bipyridazin i nanopartikkelform

Country Status (21)

Country Link
US (1) US20050153967A1 (is)
EP (1) EP1485098B1 (is)
JP (1) JP2005520824A (is)
KR (1) KR20040091133A (is)
CN (1) CN1642549A (is)
AT (1) ATE350038T1 (is)
AU (1) AU2003208709A1 (is)
BR (1) BR0307427A (is)
CA (1) CA2478758A1 (is)
DE (1) DE60310896T2 (is)
EA (1) EA007201B1 (is)
EC (1) ECSP045295A (is)
ES (1) ES2277634T3 (is)
GB (2) GB0206200D0 (is)
IS (1) IS7378A (is)
MX (1) MXPA04009008A (is)
NO (1) NO20043889L (is)
NZ (1) NZ534179A (is)
PL (1) PL372932A1 (is)
WO (1) WO2003077920A1 (is)
ZA (1) ZA200406553B (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003258630A1 (en) 2002-08-19 2004-03-11 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2203985T3 (es) * 1997-09-05 2004-04-16 Glaxo Group Limited Derivados de 2,3-diaril-pirazolo(1,5)piridazina, su preparacion y su uso como inhibidores de la ciclooxigenasa 2(cox-2)`.
EA008242B1 (ru) * 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
KR100786927B1 (ko) * 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법

Also Published As

Publication number Publication date
EA007201B1 (ru) 2006-08-25
ZA200406553B (en) 2005-09-22
BR0307427A (pt) 2004-12-28
EP1485098A1 (en) 2004-12-15
KR20040091133A (ko) 2004-10-27
MXPA04009008A (es) 2004-12-07
CN1642549A (zh) 2005-07-20
NZ534179A (en) 2006-07-28
JP2005520824A (ja) 2005-07-14
GB2402335A (en) 2004-12-08
DE60310896D1 (de) 2007-02-15
US20050153967A1 (en) 2005-07-14
PL372932A1 (en) 2005-08-08
AU2003208709A1 (en) 2003-09-29
EP1485098B1 (en) 2007-01-03
GB0419971D0 (en) 2004-10-13
EA200400864A1 (ru) 2005-02-24
GB2402335B (en) 2005-10-12
ECSP045295A (es) 2004-10-26
GB0206200D0 (en) 2002-05-01
ES2277634T3 (es) 2007-07-16
ATE350038T1 (de) 2007-01-15
DE60310896T2 (de) 2007-05-10
WO2003077920A1 (en) 2003-09-25
CA2478758A1 (en) 2003-09-25
IS7378A (is) 2004-07-29

Similar Documents

Publication Publication Date Title
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BG106586A (en) Pyrazolopyramidines as therapeutic agents
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
GEP20074123B (en) Amino acids with affinity for the alpha−2−delta−protein
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
SE9803518D0 (sv) Novel compounds
UY27979A1 (es) Indoles sustituidos en posición 2,4
BR0113389A (pt) Compostos que inibem a atividade do fator xa
WO2003053971A8 (en) Pyridoquinoxaline antivirals
BR0314843A (pt) Novo composto
YU86701A (sh) Jedinjenja i formulacije za inhibiciju agregacije proteina i snimanje amiloidnih naslaga
SE9902935D0 (sv) Pharmaceutical compositions
SE9803773D0 (sv) Compounds
SE9902937D0 (sv) Pharmaceutical compositions
GB2402335B (en) Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form
SE0102641D0 (sv) Novel compounds
SE9902938D0 (sv) Pharmaceutical compositions
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
SE9902936D0 (sv) Pharmaceutical compositions
BR0213463A (pt) Composições farmacêuticas contendo macrólidos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application